Results 201 to 210 of about 81,958 (262)

R2eGIN: Residual Reconstruction Enhanced Graph Isomorphism Network for Accurate Prediction of Poly (ADP-Ribose) Polymerase Inhibitors. [PDF]

Bioinform Biol Insights
Zonyfar C, Njimbouom SN, Mosalla S, Kim JD.   +3 more
europepmc   +1 more source

Physapubescin B From Physalis: A Food‐Derived Withanolide for Cancer Chemoprevention and Nutraceutical Development

eFood, Volume 7, Issue 4, August 2026.
Physapubescin B may interfere with multiple cancer‐associated signaling pathways by inhibiting Ras/Raf/mitogen‐activated protein kinase kinase/extracellular signal‐regulated kinase (Ras/Raf/MEK/ERK) signaling and vascular endothelial growth factor (VEGF)‐dependent angiogenesis.
Wojciech Koch, Katarzyna Stępnik, Anna Wawruszak, Estera Okoń, Agata Jarząb, Katarzyna Gaweł‐Bęben, Magdalena Michalak‐Tomczyk, Jacek Jachuła, Magdalena Zdziebło, Paweł Helon, Javad Sharifi‐Rad, Daniela Calina   +11 more
wiley   +1 more source

Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors. [PDF]

Curr Breast Cancer Rep
Ray A, Opyrchal M.
europepmc   +1 more source

Ryanodine Receptor 1 Is Dispensable for CD4+ T‐Cell Differentiation and Effector Function in Intestinal Inflammation Models

European Journal of Immunology, Volume 56, Issue 8, August 2026.
Ryr1 deletion reduces Ca2+ microdomains and delays global Ca2+ signaling in naïve CD4+ T cells but does not impair their activation, proliferation, or differentiation in vitro. Despite altered Ca2+ signaling, Ryr1 expression in CD4+ T cells was dispensable for their pathogenicity in murine models of intestinal inflammation.
Sogol Dostiar Tabrizi, Mikolaj Nawrocki, Tanja Bedke, Marius Böttcher, Friederike Stumme, Melina Birus, Franziska Möckl, Lola Hernandez, Björn‐Phillip Diercks, Nicola Gagliani, Dmitri Lodygin, Alexander Flügel, Andreas H. Guse, Hans‐Willi Mittrücker, Samuel Huber   +14 more
wiley   +1 more source

A phase I clinical trial evaluating the effect of food on the pharmacokinetics of TSL-1502, a glucuronide prodrug of a novel oral poly (ADP-ribose) polymerase inhibitor, in healthy Chinese subjects. [PDF]

Front Pharmacol
Zhou J, Mi X, Liu H, Liu R, Zhang H, Ding Y.   +5 more
europepmc   +1 more source

The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches—A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Neuroblastoma is the most common extracranial solid tumor and contributes the most to pediatric oncology deaths worldwide. Its clinical manifestations are heterogeneous, including relapses, and the prognosis remains poor, especially for high‐risk patients.
Mosammat Jannatul Mawa, Mohammad Shahangir Biswas, Maksudul Haque, Munna Kumar Podder   +3 more
wiley   +1 more source

Poly (ADP-Ribose) Polymerase Inhibition Attenuates Atherosclerotic Plaque Development in ApoE-/- Mice with Hyperhomocysteinemia. [PDF]

J Atheroscler Thromb
Xie JJ, Yu X, Liao YH, Chen J, Yao R, Chen Y, Liao MY, Ding YJ, Tang TT, Cheng X.   +9 more
europepmc   +1 more source

Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis. [PDF]

J Mol Med (Berl)
Lin CY, Chao AS, Chao A, Wu RC, Yu AL, Fu CH, Teng YC, Huang RY, Lai CH.   +8 more
europepmc   +1 more source

Poly(ADP-ribose) polymerase 1 orchestrates vascular smooth muscle cell homeostasis in arterial disease. [PDF]

Exp Mol Med
Xu W, Wu Y, Mao R, Jia Y, Jiang H, Zhang F, Huang D, He X, Wang C, Huang K.   +9 more
europepmc   +1 more source

The poly (ADP-ribose) polymerase inhibitor olaparib attenuates established pulmonary fibrosis in a large animal model. [PDF]

BMC Pulm Med
Derseh HB, Davies AN, Young A, Bischof S, Pelle J, Rudd D, McIntosh M, Piedrafita D, Bischof RJ.   +8 more
europepmc   +1 more source